Mavacamten’s therapeutic impact: cardiac-specific myosin inhibition in obstructive hypertrophic cardiomyopathy
Global Cardiology · 05.11.2024 · 2 (3)
DOI: 10.4081/cardio.2024.48 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global Cardiology, online erschienen am 05.11.2024. Verfasst von Ahmad Shabbir und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Dear Editor, Obstructive hypertrophic cardiomyopathy (oHCM) is a hereditary cardiac condition, affecting 1 in about 500 individuals, characterized by an atypical thickening of the heart muscle, specifically the interventricular septum...
Zitieren
APA
Shabbir, A., Yumn, L., & Khan, E. (2024). Mavacamten’s therapeutic impact: cardiac-specific myosin inhibition in obstructive hypertrophic cardiomyopathy. Global Cardiology, 2(3). https://doi.org/10.4081/cardio.2024.48
Vancouver
Shabbir A, Yumn L, Khan E. Mavacamten’s therapeutic impact: cardiac-specific myosin inhibition in obstructive hypertrophic cardiomyopathy. Global Cardiology. 2024;2(3). doi:10.4081/cardio.2024.48
BibTeX
@article{Shabbir2024,
author = {Shabbir, Ahmad and Yumn, Laiba and Khan, Esha},
title = {Mavacamten’s therapeutic impact: cardiac-specific myosin inhibition in obstructive hypertrophic cardiomyopathy},
journal = {Global Cardiology},
year = {2024},
volume = {2},
number = {3},
doi = {10.4081/cardio.2024.48}
}
EUVIMED